Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of TAK-659 in Advanced Solid Tumors and Lymphomas
NCT03359733Phase 1Withdrawn
- Sponsor
- Calithera Biosciences
- Start
- Feb 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mivavotinib in solid tumor (advanced stage) and lymphoma (2 arms), sponsored by Calithera Biosciences. Primary endpoints: Maximum Observed Plasma Concentration at Day 8, Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration at Day 8 and 1 more. Planned start Feb 2018; status: withdrawn.
02
Drugs
mivavotinib
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT03359733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03359733.